PCI Pharma Services is investing over $20 million to support and expand its efforts in biologic medicines and advanced injectable delivery forms.
The investment will see the company add expanded biotech clinical and commercial packaging and release testing capability at its Centre of Excellence in Philadelphia, as well as expanded cold chain capacity at numerous global locations to further support existing infrastructure.
PCI said the latest investment will include capacity expansion for cutting edge technologies for the labelling and assembly of state-of-the-art safety syringes, autoinjector and pen devices with integrated high speed cartooning, in-line serialisation, as well as furthering its onsite cold chain storage.
Salim Haffar, CEO of PCI, said: “It’s estimated that close to 40% of all medicines in pipeline development are biologic, and amazing new therapies are being developed and commercialized every day.
“With the development and commercialisation wave of biologic medicines, the market is rapidly evolving. We are proud to be the partner of choice for drug development companies as they look to outsource these specialised requirements for clinical and commercial packaging.”